bluebird bio, Inc.
BLUEDelisted Jun 2, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001293971
bluebird bio, Inc. was delisted on Jun 2, 2025; its insiders filed their last Form 4 on Jun 3, 2025; 85 institutions reported holding it in 13F filings for Q1 2025, worth $17.1M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 85
- Q1 2025, +4 vs. previous quarter
- 13F value
- $17.1M
- Reported value at the end of Q1 2025
- Superinvestors holding
- 0
- At the end of Q1 2025
Superinvestors holding BLUE, Q1 2025
No superinvestor reported holding BLUE at the end of Q1 2025.
Latest insider trades
Open-market purchases and sales by bluebird bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2025 (view filing) | Mar 3 | 2 days | Colvin Richard AChief Medical Officer | SSale | −584 | $3.92 | −$2.29K | −7.1%7.61K after | 10b5-1 |
| Mar 5, 2025 (view filing) | Mar 3 | 2 days | Klima Thomas JSee Remarks | SSale | −500 | $3.92 | −$1.96K | −6.0%7.88K after | 10b5-1 |
| Mar 5, 2025 (view filing) | Mar 3 | 2 days | Obenshain AndrewPresident and CEO | SSale | −921 | $3.92 | −$3.61K | −4.8%18.3K after | 10b5-1 |
| Feb 5, 2025 (view filing) | Feb 3 | 2 days | Klima Thomas JSee Remarks | SSale | −122 | $7.39 | −$901.58 | −1.4%8.38K after | 10b5-1 |
| Feb 5, 2025 (view filing) | Feb 3 | 2 days | Colvin Richard AChief Medical Officer | SSale | −64 | $7.39 | −$472.96 | −0.8%8.19K after | 10b5-1 |
| Feb 5, 2025 (view filing) | Feb 3 | 2 days | Vittiglio JosephChief Business & Legal Officer | SSale | −238 | $7.39 | −$1.76K | −5.0%4.50K after | 10b5-1 |
| Feb 5, 2025 (view filing) | Feb 3 | 2 days | Obenshain AndrewPresident and CEO | SSale | −86 | $7.39 | −$635.54 | −0.5%18.5K after | 10b5-1 |
| Jan 8, 2025 (view filing) | Jan 6 | 2 days | Colvin Richard AChief Medical Officer | SSale | −19 | $9.24 | −$175.56 | −0.2%8.26K after | 10b5-1 |
| Jan 8, 2025 (view filing) | Jan 6 | 2 days | Obenshain AndrewPresident and CEO | SSale | −140 | $9.24 | −$1.29K | −0.7%18.6K after | 10b5-1 |
| Dec 12, 2024 (view filing)4:01 PM ET | Dec 10 | 2 days | Obenshain AndrewPresident and CEO | SSale | −971 | $0.4173 | −$405.2 | −0.3%374.2K after | 10b5-1 |
Top 10 13F holders, Q1 2025
The largest institutional positions in bluebird bio, Inc. at the end of Q1 2025; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 697,973 | $3.41M | 0.00% | −10,696−1.5% | Reduced |
| Vanguard Group Inc | 518,238 | $2.53M | 0.00% | −7,176−1.4% | Reduced |
| Tang Capital Management LLC | 400,000 | $1.95M | 0.11% | +400,000 | New |
| Geode Capital Management, LLC | 246,117 | $1.20M | 0.00% | +12,603+5.4% | Added |
| State Street Corp | 196,179 | $957.4K | 0.00% | −1,742−0.9% | Reduced |
| Credit Industriel Et Commercial | 150,000 | $732.0K | 0.13% | +150,000 | New |
| Groupe la Francaise | 135,000 | $679.0K | 0.01% | +135,000 | New |
| Equitec Proprietary Markets, LLC | 110,714 | $540.3K | 1.55% | +110,714 | New |
| FMR LLC | 87,667 | $427.8K | 0.00% | +40,039+84.1% | Added |
| Quinn Opportunity Partners LLC | 81,429 | $397.4K | 0.03% | +81,429 | New |